Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported R&D Expense of $145.64 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $145.64M | +75.2% |
| 2024 | $83.11M | +153.1% |
| 2023 | $32.84M | +11.8% |
| 2022 | $29.38M | -37.2% |
| 2021 | $46.77M | -7.6% |
| 2020 | $50.62M | -14.5% |
| 2019 | $59.21M | +43.2% |
| 2018 | $41.34M | +48.2% |
| 2017 | $27.90M | +382.5% |
| 2016 | $5.78M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.49M | +27.2% | +23.8% |
| June 30, 2025 | $26.25M | +45.3% | -2.8% |
| March 31, 2025 | $27.00M | +106.5% | +5.7% |
| September 30, 2024 | $25.54M | +220.9% | +41.4% |
| June 30, 2024 | $18.07M | +76.2% | +38.2% |
| March 31, 2024 | $13.08M | +123.7% | +64.3% |
| September 30, 2023 | $7.96M | +10.3% | -22.4% |
| June 30, 2023 | $10.25M | -11.6% | +75.4% |
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +75.2% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Dianthus Therapeutics, Inc. /DE/’s r&d expense has grown by 2418.8% (from $5.78 million to $145.64 million).
- The most recent figure is from Dianthus Therapeutics, Inc. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: